A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors
Latest Information Update: 04 Nov 2026
At a glance
- Drugs Nivolumab (Primary) ; Tucidinostat (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors HUYA Bioscience International
Most Recent Events
- 19 Oct 2026 Planned number of patients changed from 480 to 455.
- 29 Sep 2026 According to a HUYABIO International media release, data from the trial will be presented in an oral Proffered Paper session at ESMO Congress 2026
- 24 Jul 2026 Results presented in the Meiji Seika Pharma media release,